Recently, we reported that STAP-2 binds to BCR-ABL via its SH2-like domain, and enhances proliferation of CML cells as well as their resistance to imatinib [32]. Here, STAP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.